World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Best Scientists

D-Index
164
Citations
173709
World Ranking
1057
National Ranking
53

Medicine

D-Index
168
Citations
188357
World Ranking
548
National Ranking
21

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Dirk Schadendorf is affiliated with the University of Duisburg-Essen in Germany. The primary research focus spans medicine and biochemistry, genetics, and molecular biology, with significant contributions to oncology, molecular biology, immunology, epidemiology, and pulmonary and respiratory medicine.

Their research covers a range of topics related predominantly to cancer and immunotherapy. Key areas of work include:

  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • CAR-T Cell Therapy Research
  • Immunotherapy and Immune Responses
  • Nonmelanoma Skin Cancer Studies
  • Colorectal Cancer Treatments and Studies

Among Schadendorf's frequently published venues are:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancers

Schadendorf has collaborated extensively with several coauthors, including:

  • Paolo A. Ascierto
  • Ralf Gutzmer
  • Lisa Zimmer
  • Elisabeth Livingstone
  • Georgina V. Long

Recent notable publications include:

  • "Tertiary lymphoid structures improve immunotherapy and survival in melanoma," 2020, Nature
  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours," 2021, Annals of Oncology
  • "Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial," 2020, The Lancet Oncology
  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

    Frank O. Nestle;Selma Alijagic;Michel Gilliet;Yuansheng Sun

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • A landscape of driver mutations in melanoma

    Eran Hodis;Ian R. Watson;Ian R. Watson;Gregory V. Kryukov;Gregory V. Kryukov;Gregory V. Kryukov;Stefan T. Arold

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • TERT Promoter Mutations in Familial and Sporadic Melanoma

    Susanne Horn;Adina Figl;P. Sivaramakrishna Rachakonda;Christine Fischer

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

Frequent Co-Authors

Axel Hauschild
Axel Hauschild Kiel University
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Georgina V. Long
Georgina V. Long University of Sydney
Antje Sucker
Antje Sucker University of Duisburg-Essen
Caroline Robert
Caroline Robert University of Paris-Saclay
Jochen Utikal
Jochen Utikal German Cancer Research Center
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Ralf Gutzmer
Ralf Gutzmer Hannover Medical School
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine extends far beyond traditional paths. Many prospective healthcare professionals start—or advance—their careers with flexible online degree options. For example, a growing number of students are enrolling in online nursing programs to gain essential clinical skills and earn their qualifications remotely.

Registered nurses looking to enhance their expertise often seek the cheapest rn to bsn online programs, which provide a cost-effective route to a Bachelor of Science in Nursing. For those aspiring to leadership, education, or research roles, pursuing an PhD in nursing can provide advanced knowledge and open new career opportunities.

Non-nurses who hold a bachelor’s degree in another field may consider the online direct entry msn option—a pathway that allows individuals to switch careers and enter advanced nursing roles efficiently. These online programs deliver flexibility, affordability, and accessibility, enabling a wider range of students to participate in the healthcare workforce.

Best Scientists Citing Dirk Schadendorf

Trending Scientists